Physician profile
Sunyoung S Lee
NPI 1003159054
$21,152.58
in general payments reported to CMS, 2019-2025
9 companies · $3,615 in 2025
The $3,615 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.28 · 2022: $144 · 2023: $9,203 · 2024: $8,172 · 2025: $3,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Travel and Lodging: $1,804 · Food and Beverage: $1,536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,650.00 |
| Travel and Lodging | $1,803.97 |
| Food and Beverage | $1,535.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $10,873.61 | 2024-2025 | Imfinzi |
| Jazz Pharmaceuticals INC. | $7,880.31 | 2023-2024 | |
| Incyte Corporation | $1,534.45 | 2023 | |
| Boston Scientific Corporation | $337.73 | 2022-2024 | |
| Intera Oncology, INC | $332.20 | 2025 | Intera |
| Exelixis INC. | $175.00 | 2025 | Cabometyx |
| Abbott Laboratories | $19.28 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunyoung Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.